Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 14/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5858602 | 0.94 | KCNA3 (0.59) | KCNA3CCR5CYP2D6OPRL1DPP4 | |
| SCHEMBL6079135 | 0.88 | KCNA3 (0.64) | KCNA3CCR5CYP2D6OPRL1OPRM1 | |
| SCHEMBL6079142 | 0.88 | KCNA3 (0.64) | KCNA3CCR5CYP2D6OPRL1OPRM1 | |
| SCHEMBL6079873 | 0.88 | KCNA3 (0.64) | KCNA3CCR5CYP2D6OPRL1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL1920904 | 0.83 | DPP4 (0.47) | KCNA3DPP4DPP7OPRM1 | |
| Trifluoroacetic Acid SCHEMBL5857174 | 0.82 | SLC6A2 (0.53) | CCR5DPP4DPP7 | |
| SCHEMBL5857950 | 0.80 | KCNA3 (0.71) | KCNA3CCR5CYP2D6OPRL1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL19613524 | 0.80 | DRD2 (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL19613522 | 0.80 | DRD2 (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL28249914 | 0.80 | ARG1 (0.45) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | KCNA3 2564/4885CCR5 1/4885CYP2D6 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.